GT Biopharma (GTBP)
(Delayed Data from NSDQ)
$2.05 USD
-0.03 (-1.44%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.06 +0.01 (0.49%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.05 USD
-0.03 (-1.44%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.06 +0.01 (0.49%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
GT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy
by Zacks Equity Research
GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Albireo Pharma (ALBO) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
Has Geron (GERN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Geron (GERN) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
Has Ensign Group (ENSG) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Ensign Group (ENSG) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
OXIS International Inc. (GTBP) Loses 32.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for OXIS International Inc. (GTBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
OXIS International Inc. (GTBP) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
OXIS International Inc. (GTBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
OXIS International Inc. (GTBP) closed the most recent trading day at $12.51, moving +1.54% from the previous trading session.
GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.
OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, OXIS International Inc. (GTBP) closed at $11.74, marking a +0.34% move from the previous day.
OXIS International Inc. (GTBP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, OXIS International Inc. (GTBP) closed at $9.64, marking a +0.63% move from the previous day.